★ Neuropeptides

Semax + Selank Combo (pre-blended)

Neuropeptides · 10mg × 10 vials

Semax + selank in one vial at moderate concentration.

✓ 98%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support

📋 Certificate of Analysis Request the third-party COA via Telegram ↗

Overview

What Is Semax + Selank Combo (pre-blended)?

The Semax + Selank blend is a single-vial co-formulation of the two best-known Russian neuropeptides. The two act on separate pathways with no receptor overlap, which is the basis for studying them together and for co-formulating them.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, a stabilised ACTH 4-10 fragment) acutely upregulates BDNF and NGF gene expression in the hippocampus and basal forebrain, modulates dopaminergic and serotonergic tone in limbic structures, and inhibits enkephalin-degrading enzymes to raise endogenous opioid signalling. In the literature these effects are associated with attention, working memory, and motivation.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, a stabilised tuftsin analogue) upregulates GABA-A receptor expression and amplifies inhibitory tone without binding the benzodiazepine site, with a parallel serotonergic arm via 5-HIAA metabolism and hippocampal BDNF upregulation. Its literature concerns anxiolysis and mood stabilisation without sedation or dependence.

Together the two cover the alerting and calming axes: Semax alone can amplify anxious arousal in already-anxious subjects in some reports, while Selank moderates that effect without removing the cognitive component. The pre-blended format carries the same total active content as the two compounds supplied separately.

Published Safety Data

What the published studies measured.

What the studies show

Measured in clinical trials

No combo-specific RCT data - neither Russian clinical literature nor Western trials have tested the pre-blended formulation as a single intervention. Side effect profile is the union of the two individual profiles.
Semax arm: headache 2-5% (mild, transient), nasal irritation 3-8% intranasal, mild BP elevation at higher doses (1.5+ mg/day), sleep disruption with late-day dosing. No serious AE signal across 25+ years of Russian post-marketing surveillance.
Selank arm: well-tolerated across all Russian trials (Zozulia 2001, Medvedev 2007-2014). No serious AEs at therapeutic dose (300-900 mcg/day intranasal up to 14 days). Mild headache <5%, rare nasal irritation, mild fatigue on first 1-2 doses in a minority.
Combined: no documented amplification of either peptide's AE profile when co-administered. The mechanisms don't compound, so AEs from the combo run at the individual rates, not summed.

The Research

Peer-reviewed studies and clinical guidelines - tap any to read the source.

Physician commentaryDr. Seeds / Peptide Society on neuropeptide pairs in clinical peptide practice

practitioner framing of Semax + Selank as the canonical neuropeptide pair

Read study ↗Physician commentaryTailor Made Compounding clinical brief on Semax and Selank

compounding pharmacy positioning for the pair

Read study ↗

Reconstitution & Storage

Storage: refrigerated, ~14-21 days after reconstitution. Stability is limited by the Semax half (Selank is more stable; the blend is bottlenecked by Semax's tolerance for reconstituted storage). Lyophilized vials room-temp short-term, refrigerated long-term.